What are the NTEP (National Tuberculosis Elimination Programme) guidelines for treating drug‑susceptible and drug‑resistant Mycobacterium tuberculosis, including recommended drug regimens, dosing, and treatment durations?

NTEP Guidelines for Mycobacterium Tuberculosis Treatment

Drug-Susceptible Pulmonary Tuberculosis

The standard treatment regimen consists of 2 months of isoniazid, rifampin, pyrazinamide, and ethambutol (2HRZE) followed by 4 months of isoniazid and rifampin (4HR), administered daily under directly observed therapy. 1, 2

Intensive Phase (First 2 Months)

• Isoniazid: 5 mg/kg up to 300 mg daily 1
• Rifampin: 10 mg/kg up to 600 mg daily 1
• Pyrazinamide: 35 mg/kg daily for patients <50 kg or 2.0 g daily for patients ≥50 kg 1
• Ethambutol: 15 mg/kg daily 1
• All four drugs must be given together; never use fewer than four drugs before drug susceptibility results are available 2

Continuation Phase (Months 3-6)

• Isoniazid and Rifampin continued for 4 additional months 1, 2
• Extend continuation phase to 7 months (total 9 months) if cavitation present on initial chest X-ray AND cultures remain positive at 2 months 1

Alternative Shorter Regimen

• A 4-month regimen may be used for culture-negative, paucibacillary tuberculosis in HIV-uninfected adults 3
• Recent 2025 guidelines support novel 4-month regimens for eligible pulmonary TB patients 4

Dosing Frequency Options

• Daily dosing (7 days/week) is preferred and most effective 1
• 5 days/week dosing acceptable when directly observed therapy is used 1
• Thrice-weekly dosing should be used with extreme caution; avoid in HIV-infected patients and those with cavitary disease 1
• Never use twice-weekly dosing in HIV-infected patients or those with smear-positive/cavitary disease 1, 2

Drug-Resistant Tuberculosis

Multidrug-Resistant TB (MDR-TB)

Use at least 5 effective drugs in the intensive phase and 4 drugs in the continuation phase, with bedaquiline and a later-generation fluoroquinolone as core components, for a total duration of 15-21 months after culture conversion. 1, 3

Core Drug Components (Strongly Recommended)

• Bedaquiline - essential component 1, 3, 5
• Later-generation fluoroquinolone (levofloxacin or moxifloxacin) 1, 3, 5
• Linezolid 1, 3, 5
• Clofazimine 1, 3, 5

Additional Drugs to Consider

• Cycloserine 1, 5
• Pyrazinamide - only if susceptibility confirmed 1, 5
• Ethambutol - only when other more effective drugs cannot be assembled 1

Treatment Duration

• Intensive phase: 5-7 months after culture conversion 1, 3
• Total duration: 15-21 months after culture conversion 1, 3

Extensively Drug-Resistant TB (XDR-TB)

Treat with at least 5 effective drugs in the intensive phase and 4 drugs in the continuation phase for 15-24 months after culture conversion, using bedaquiline, later-generation fluoroquinolone, linezolid, and clofazimine as the core regimen. 1, 5

XDR-TB Specific Considerations

• Extended duration: 15-24 months after culture conversion (longer than MDR-TB) 1, 5
• Same core drugs as MDR-TB but may require additional agents 5
• Carbapenems (imipenem-cilastatin or meropenem) must always be combined with amoxicillin-clavulanate 5
• Delamanid may be considered though evidence is limited 1, 5

Drugs to AVOID in Drug-Resistant TB

• Never use amoxicillin-clavulanate alone (only with carbapenems) 1, 5
• Never use macrolides (azithromycin, clarithromycin) - lack efficacy 1, 5
• Avoid kanamycin or capreomycin - associated with poor outcomes 5
• Avoid ethionamide/prothionamide if more effective drugs available 1, 5

Isoniazid-Resistant TB

• Use rifampin, ethambutol, pyrazinamide, and a later-generation fluoroquinolone for 6 months 3
• Pyrazinamide duration can be shortened to 2 months in noncavitary, lower burden disease 3

Special Populations

HIV Co-Infection

• Use the same 6-month regimen (2HRZE/4HR) for drug-susceptible TB 2
• Monitor carefully for rifampin drug interactions with antiretroviral agents 2
• Never use twice-weekly dosing in HIV-infected patients with CD4 <100 cells/μL 2
• Avoid intermittent dosing in all HIV-infected patients 1

CNS Tuberculosis (Meningitis)

• Extend total treatment to 12 months: 2 months HRZE followed by 10 months HR 2
• Add adjunctive corticosteroids for stages II and III disease 2

Children

• 4-month regimen recommended for children with nonsevere TB 4
• Same drug principles apply but with weight-based dosing 4

Essential Adjunctive Measures

Pyridoxine (Vitamin B6) Supplementation

• 25-50 mg daily for all patients at risk of neuropathy 1
• Risk groups include: pregnant women, breastfeeding infants, HIV-infected patients, diabetes, alcoholism, malnutrition, chronic renal failure, advanced age 1
• Increase to 100 mg daily if peripheral neuropathy develops 1

Case Management

• Patient education and counseling at every visit 1
• Use medical interpreter services for non-English speakers (not family/friends) 1
• Directly observed therapy when drugs given <7 days per week 1
• Patient reminders and follow-up systems for missed appointments 1
• Integration with primary care and mental health services 1

Critical Pitfalls to Avoid

Drug-Susceptible TB

• Never start with fewer than 4 drugs before susceptibility results 2
• Never discontinue ethambutol before drug susceptibility results available 2
• Never use intermittent dosing without guaranteed directly observed therapy 2, 3
• Missed doses with intermittent regimens lead to treatment failure and acquired resistance 1

Drug-Resistant TB

• Never use fewer than 5 effective drugs in MDR-TB intensive phase - leads to poor outcomes 3, 5
• Never treat MDR-TB without expert consultation 2, 3
• Never treat for <15 months after culture conversion - associated with higher relapse rates 5
• Using ineffective drugs counts as monotherapy and drives further resistance 1

Monitoring and Follow-Up

Treatment Response Assessment

• Sputum cultures at 2 months to assess response 1
• Monthly clinical assessment during treatment 1
• Culture conversion defines start of continuation phase countdown for drug-resistant TB 1, 3

Drug Resistance Surveillance

• Despite suboptimal plasma levels of isoniazid and rifampin observed in some NTEP patients, favorable outcomes can still be achieved, likely due to adequate pyrazinamide levels 6
• However, patients with suboptimal levels of both isoniazid and rifampin may require two-year follow-up for MDR-TB prevention 6

Latent TB Infection (LTBI) Treatment

Standard Regimens

• Prefer short-course rifamycin-based regimens (3-4 months) over longer isoniazid monotherapy 2
• Options include: 3 months of isoniazid plus rifapentine (weekly) or 4 months of rifampin (daily) 2

MDR-TB Contacts

• Offer treatment rather than observation alone 3
• Use later-generation fluoroquinolone alone or with a second drug for 6-12 months 3

Surgical Intervention

• Consider elective partial lung resection for adults with MDR-TB when clinical judgment, bacteriological, and radiographic data suggest high risk of treatment failure or relapse with medical therapy alone 3, 5